SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02455167
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1,
cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin
(or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV).
2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV)
treatment using a new test of liver function, HepQuant-SHUNT.
Name: Simeprivir (SMV)
Description: Experimental Single arm study. All participants will get the same treatment.
Type: Drug
Group Labels: 1 HCV positive group
Name: Sofosbuvir (SOF)
Description: Experimental Single arm study. All participants will get the same treatment.
Type: Drug
Group Labels: 1 HCV positive group
Name: Ribavirin (RBV)
Description: Experimental Single arm study. All participants will get the same treatment.
Type: Drug
Group Labels: 1 HCV positive group
Primary Outcomes
Measure: The sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation Time: 12 weeks
Measure: Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT. Time: 12 weeks
Purpose: Other
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
1 Q80K
Inclusion Criteria:
1. HCV genotype 1 infection (all subtypes and Q80K a type of mutation are allowed), and
have been approved by a third party payer for the FDA-approved combination of
sofosbuvir (SOF) plus ribavirin. --- Q80K ---